Company profile: Aliada Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology therapies for central nervous system diseases, leveraging the MODEL platform to deliver large molecules across the blood-brain barrier via small modular protein domains. Offerings include ALIA-1758, a bispecific antibody targeting pyroglutamate amyloid beta and TfR for potentially clearing amyloid beta plaques in Alzheimer’s disease, and partner programs to develop brain-accessible therapeutics for lysosomal storage disorders.
Products and services
- ALIA-1758: A bispecific antibody targeting pyroglutamate amyloid beta and TfR to potentially clear amyloid beta plaques in Alzheimer's disease patients
- MODEL platform: A modular platform engineered to deliver large molecules across the blood-brain barrier using small protein domains for efficient BBB transport and therapeutic functionality
- Partner Programs: Brain-access collaborations with entities like Chiesi Global Rare Diseases to develop therapeutics for lysosomal storage disorders with brain access, aligned to CNS disease treatment goals
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aliada Therapeutics
BioBridges
HQ: United States
Website
- Description: Provider of flexible expertise, services, and technologies for life sciences companies from discovery through commercialization, offering clinical operations, data management, regulatory affairs, safety & pharmacovigilance, biostatistics, and medical affairs to support studies, compliance, safety, and post-approval lifecycle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioBridges company profile →
Doppel Farmaceutici
HQ: Italy
Website
- Description: Provider of contract development and manufacturing for pharmaceutical and nutritional products, covering formulation, development, manufacturing, packaging, marketing and post-marketing controls. Delivers R&D for formulation/analytical methods, clinical trial batches and regulatory consultancy. Manufactures solids, semi-solids, liquids, sprays, sterile products, injectables, medical devices, soft gelatin capsules, highly potent drugs, and food/effervescent supplements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Doppel Farmaceutici company profile →
Carbogen Amcis
HQ: Switzerland
Website
- Description: Provider of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries, including CDMO support for drug substances and drug products, high potency API development and manufacturing, production of cholesterol, lanolin derivatives and vitamin D/D2 analogs, integrated analytical services, and non-GMP manufacturing of starting materials, intermediates, fine and specialty chemicals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carbogen Amcis company profile →
Molecular Neuroimaging
HQ: United States
Website
- Description: Provider of neuroimaging services as a biotechnology firm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Neuroimaging company profile →
Bachem
HQ: Switzerland
Website
- Description: Provider of full-service biochemicals to the pharma and biotech industry; an independent, technology-based company specializing in process development and GMP manufacturing of peptide and oligonucleotide APIs, complex organic molecules, and innovative research biochemicals. Offers research-grade and GMP peptides, oligonucleotide NCE development, commercial APIs and generics, catalog peptides, custom peptide synthesis, amino acid derivatives, and products for diagnostics and cosmetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bachem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aliada Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aliada Therapeutics
2.2 - Growth funds investing in similar companies to Aliada Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aliada Therapeutics
4.2 - Public trading comparable groups for Aliada Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →